AR059555A1 - Metodos para el tratamiento de degeneracion macular y condiciones oculares relacionadas - Google Patents

Metodos para el tratamiento de degeneracion macular y condiciones oculares relacionadas

Info

Publication number
AR059555A1
AR059555A1 ARP070100697A ARP070100697A AR059555A1 AR 059555 A1 AR059555 A1 AR 059555A1 AR P070100697 A ARP070100697 A AR P070100697A AR P070100697 A ARP070100697 A AR P070100697A AR 059555 A1 AR059555 A1 AR 059555A1
Authority
AR
Argentina
Prior art keywords
macular degeneration
treatment
methods
eye conditions
related eye
Prior art date
Application number
ARP070100697A
Other languages
English (en)
Original Assignee
Pfizer
Brigham & Womens Hospital
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Brigham & Womens Hospital, Beth Israel Hospital filed Critical Pfizer
Publication of AR059555A1 publication Critical patent/AR059555A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un complejo AIM-lípido para tratar la degeneracion macular relacionada con el envejecimiento y condiciones relacionadas. Las composiciones y los métodos abarcan un nuevo enfoque para el tratamiento de degeneracion macular relacionada con el envejecimiento y condiciones relacionadas. También se proveen composiciones farmacéuticas para este uso.
ARP070100697A 2006-02-17 2007-02-16 Metodos para el tratamiento de degeneracion macular y condiciones oculares relacionadas AR059555A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77433106P 2006-02-17 2006-02-17
US77591506P 2006-02-22 2006-02-22

Publications (1)

Publication Number Publication Date
AR059555A1 true AR059555A1 (es) 2008-04-09

Family

ID=38437932

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100697A AR059555A1 (es) 2006-02-17 2007-02-16 Metodos para el tratamiento de degeneracion macular y condiciones oculares relacionadas

Country Status (5)

Country Link
US (1) US20070254832A1 (es)
JP (1) JP2007269778A (es)
AR (1) AR059555A1 (es)
TW (1) TW200808335A (es)
WO (1) WO2007098122A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2279730B1 (es) * 2006-02-14 2008-08-01 Italfarmaco, S.A. Uso de derivados del acido sulfonico en el tratamiento de enfermedades vasoproliferativas oculares.
BR112012013303A2 (pt) * 2009-12-04 2016-03-01 Euclid Systems Corp composições farmacêuticas e respectivos usos
MX2012014928A (es) 2010-06-30 2013-03-22 Csl Ltd Una formulacion de lipoproteina de alta densidad reconstituida y metodo de produccion de la misma.
MX2013002145A (es) 2010-08-30 2013-04-03 Hoffmann La Roche Tetranectina-apolipoproteina a-i, particulas lipidicas que la contienen y utilizacion de la misma.
KR101424217B1 (ko) 2011-05-18 2014-08-13 다이아텍코리아 주식회사 노년 황반변성의 진단, 치료 및 예방용 조성물 및 노년 황반변성에 대한 정보를 얻기 위한 방법
BR112013033562A2 (pt) 2011-08-25 2017-02-14 Hoffmann La Roche proteína de fusão de tetranectina-apolipoproteína a-i encurtada, uma partícula de lipídio que a contém e uso das mesmas
US9125943B2 (en) * 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation
CA2998504C (en) * 2015-09-21 2023-06-20 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
WO2017222042A1 (ja) * 2016-06-24 2017-12-28 国立大学法人京都大学 眼用医薬組成物
KR20190124704A (ko) * 2017-01-24 2019-11-05 마크레젠, 인크. 아포지질단백질 모방체를 이용하는, 나이 관련 황반 변성 및 기타 안질환의 치료
US10426817B2 (en) * 2017-01-24 2019-10-01 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
WO2018172850A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
MX2023003877A (es) * 2020-10-01 2023-04-18 Abionyx Pharma Sa Composiciones que comprenden complejos basados en proteina de union a lipidos para usarse en el tratamiento de enfermedades oculares.
AU2023267836A1 (en) * 2022-05-13 2024-11-21 Character Biosciences, Inc. Therapeutic lipid processing compositions and methods for treating age-related macular degeneration

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
SE9203753D0 (sv) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
US5824685A (en) * 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
JP3257391B2 (ja) * 1996-03-18 2002-02-18 東洋インキ製造株式会社 インクジェット記録液
SE9603304D0 (sv) * 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) * 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
DE10141018A1 (de) * 2001-08-22 2003-03-13 Eth Zuerich Eidgenoessische Te Verwendung von negativ geladenen Phospholipiden, sowie Zusammensetzungen umfassend Phospholipide zur Behandlung des Auges
AU2002362612B2 (en) * 2001-09-28 2007-11-15 Cedars-Sinai Medical Center Prevention and treatment of restenosis by local administration of drug
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
BR0310100A (pt) * 2002-05-17 2007-04-27 Esperion Therapeutics Inc métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto
PE20050438A1 (es) * 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
US7427662B2 (en) * 2005-02-01 2008-09-23 Baord Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Inhibition of angiogenesis and destruction of angiogenic vessels by apolipoprotein A-I and high density lipoprotein

Also Published As

Publication number Publication date
JP2007269778A (ja) 2007-10-18
TW200808335A (en) 2008-02-16
WO2007098122A3 (en) 2008-07-03
US20070254832A1 (en) 2007-11-01
WO2007098122A2 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
AR059555A1 (es) Metodos para el tratamiento de degeneracion macular y condiciones oculares relacionadas
CL2008003096A1 (es) Compuestos derivados de piperidino-dihidrotienopirimidinas; inhibidores pde4; composicion farmaceutica que los comprende; y uso en el tratamiento de trastornos o enfermedades de las vias respiratorias o gastrointestinales, como tambien enfermedades inflamatorias de las articulaciones u ojos, entre otras.
CY1120741T1 (el) Θεραπεια οζωδους σκληρυνσης
DOP2013000036A (es) Derivados de ciclobutano como inhibidores de jak
CL2014000032A1 (es) Compuestos derivados de bencilamina, inhibidores de calicreina plasmatica; composicion farmaceutica; y su uso para el tratamiento de agudeza visual deteriorada, retinopatia diabetica, edema macular diabetico, hipotension cardiomiopatia, cancer, entre otros
CL2008001259A1 (es) Uso de una composicion que comprende un inhibidor del factor d del complemento para preparar un medicamento util para la inhibicion de la perdida de agudeza visual ociada con la degeneracion macular relacionada con la edad.
UY34220A (es) Indazoles, composiciones farmacéuticas y uso de los mismos
MX2015003140A (es) Formulaciones de enzalutamida.
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
ECSP088590A (es) Derivados de aminoácido multicíclicos y sus métodos de uso
UY33865A (es) Derivados Heterocíclicos Novedosos y su Uso en el Tratamiento de Trastornos Neurológicos
UY34278A (es) Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CO6501189A2 (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
CR11731A (es) Composiciones y procedimientos para su preparación y uso
ECSP11011011A (es) Derivados de acido 1-amino-2-ciclobutiletilborónico
ECSP11011067A (es) Compuestos para el tratamiento de enfermedades y desórdenes oftalmológicos
UY33314A (es) Derivados de acido 1-amino-2-ciclopropiletilboronico
ECSP17074645A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
CR20140275A (es) Triazolopiridinas sustituidas
CR11199A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
CR11373A (es) COMPUESTOS DE TIENOPIRIMIDINA Y PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE mTOR CINASA Y PI3 CINASA
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.

Legal Events

Date Code Title Description
FB Suspension of granting procedure